Copyright ©The Author(s) 2022.
World J Clin Cases. Sep 26, 2022; 10(27): 9703-9713
Published online Sep 26, 2022. doi: 10.12998/wjcc.v10.i27.9703
Figure 1
Figure 1 Preferred reporting items for systematic assessment flow diagram showing the exclusion and inclusion of trials in this systematic evaluation of gemcitabine plus nab-paclitaxel + a targeted drug in metastatic pancreatic cancer. GA: Gemcitabine plus nab-paclitaxel; RCTs: Randomized control trials.
Figure 2
Figure 2  Forest plots of overall survival.
Figure 3
Figure 3  Forest plots of progression-free survival.
Figure 4
Figure 4  Forest plots of objective response rates.